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Purpose: Tenosynovial giant cell tumor (TGCT), a
rare locally aggressive neoplasm of the synovium of
joints and tendon sheaths, is associated with joint
destruction, inﬂammation, pain, and swelling, in
part due to colony-stimulating factor 1 receptor–
bearing macrophages recruited to the tumor by
genetic elevation of colony-stimulating factor 1
activity. The most common treatment is surgery,
although promising pharmacologic treatments are in
development. Patient-reported outcome (PRO) instru-
ments are critical end points in demonstrating the
clinical relevance of standard oncologic outcome meas-
ures and the overall impact of novel pharmacologic
therapies in nonmalignant neoplastic conditions such as
TGCT. The content validity of PROs relevant to
patients with TGCT has not been formally investigated,Scan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
phone must have a QR Code reader installed.
778and instruments to evaluate such outcomes do not exist
for this condition.
Methods: PRO instruments of potential relevance
were evaluated by using a literature review and by clinical
and PRO experts. Patients with TGCT were recruited
through clinical sites and the Internet for participation in
qualitative research interviews to identify predominant
symptoms and to test the relevance and content validity
of several PRO measures. Select PRO measures were
included in a Phase I clinical trial, and preliminary results
of the PRO end points are reported descriptively.
Findings: Of the 22 subjects who participated in
qualitative interviews, 73% were female, and their
mean age was 42.5 years (range, 27–56 years). The
TGCTs (19 diffuse and 3 localized) were located in the
knee (n ¼ 15), hip (n ¼ 3), ankle (n ¼ 2), elbow
(n ¼ 1), and forearm (n ¼ 1). The most commonAccepted for publication March 7, 2016.
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H.L. Gelhorn et al.symptoms cited were pain (82%), swelling (86%),
stiffness (73%), reduced range of motion (64%), and
joint instability (64%), which were consistent with
clinical expert input and with the content of instru-
ments chosen by PRO experts. The worst pain
numeric rating scale, Patient Reported Outcomes
Measurement Information System physical function-
ing items, and the Western Ontario and McMaster
Universities Osteoarthritis Index, as well as a worst
stiffness numeric rating scale developed for TGCT, were
conﬁrmed as meaningful measures of TGCT patient
symptoms and were well understood in qualitative inter-
views. Results from the Phase I trial showed trends of
improvement in both pain and stiffness over time.
Implications: This study is the ﬁrst to gather
information directly from patients with TGCT regard-
ing their symptom experiences. Pain, stiffness, and
physical functioning are important treatment out-
comes in patients with TGCT. We have identiﬁed
content-valid PRO measures of these concepts, which
are included in an ongoing Phase III TGCT clinical
trial with pexidartinib (PLX3397) (NCT02371369).
(Clin Ther. 2016;38:778–793) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
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Pigmented villonodular synovitis (PVNS) and giant
cell tumors of the tendon sheath (GCT-TS) are
members of a single condition referred to as tenosy-
novial giant cell tumor (TGCT), localized and diffuse
type, and have a common pathogenesis.1 They are
proliferative neoplasms involving the synovium and
tendon sheaths that typically present in young and
middle-aged adults of both sexes. Diffuse-type TGCT
tends to be more aggressive, often recurring locally
(8%–56%) after surgery, and is capable of malignant
transformation.2 In a retrospective analysis of 49
previously untreated patients with PVNS of the knee
(12 localized, 37 diffuse), the overall relapse rate after
surgery was 43%, with 52% of diffuse-type relapsing
within 5 years.3
Although rare, TGCTs are likely underreported and
underdiagnosed, with an estimated overall annualApril 2016incidence in the United States of 11 cases per million,
including 1.8 cases per million for PVNS, and 9.2 cases
per million for GCT-TS.4 More recent nationwide
pathology data from the Netherlands estimate the
annual incidence of TGCTs to be 49.7 cases per million.5
The current standard of care for TGCT is surgical
resection of the tumor as completely as possible to
reduce symptoms and joint destruction, improve func-
tion, and minimize the risk of recurrence.6 Although
surgery is the standard of care, it has been observed
that expression of the colony-stimulating factor 1 gene
is elevated in most TGCT tumors7 and may, in many
cases, be driven by a gene translocation.8,9 This
possibility has led to the development of therapies
targeting the colony-stimulating factor 1 receptor for
which regression in tumor volume is the primary
indicator of response.10
For both clinicians and regulators to evaluate the
relevance of treatment effects for patients, it is critical
to understand the symptoms that patients experience
and whether tumor shrinkage improves these symp-
toms and patients’ health-related quality of life.
Although tumor volume is a critical end point of
new therapeutic agents, patient-reported outcome
(PRO) instruments inform the clinical relevance of
standard oncologic end points and treatment beneﬁts
from the patient perspective. PRO data are essential to
understand the appropriate clinical application of a
targeted therapy in this neoplastic condition with
varying clinical sequelae. This is particularly true for
TGCT, a rarely lethal but morbid tumor, in which the
duration of systemic therapy is likely to be much
longer with a more lengthy window of exposure to
toxicities, compared with malignant tumors in which
the duration of exposure to systemic agents is limited
by a patient’s life span.11
There is a dearth of PRO research among patients
with TGCT; to our knowledge, 3 studies have
reported on PRO outcomes assessed in this popula-
tion by using standardized instruments.12–14 To date,
symptom measures and other PROs relevant to
patients with TGCT have not been formally re-
searched, and PRO instruments validated among
patients with TGCT do not currently exist. Thus, a
qualitative interview study was completed to identify
and characterize symptoms associated with TGCT and
to evaluate several PRO instruments that could appro-
priately assess these symptoms in the context of a
clinical trial.779
Clinical TherapeuticsPATIENTS AND METHODS
Overall Study Design
This study was designed to: (1) identify symptoms
that are experienced by patients with TGCT; and (2)
evaluate the content validity of several potentially
relevant PRO instruments among patients with
TGCT. The study consisted of a targeted literature
review, interviews with clinical experts, and cross-
sectional, qualitative semi-structured interviews with
patients.
Select PRO instruments were identiﬁed, tested, and
reﬁned through the qualitative research with patients
and were then incorporated into a Phase I trial
(NCT01004861) to provide a preliminary evaluation
of the feasibility and value of including these PRO
measures as supportive end points. Speciﬁcally, the
pain and stiffness numeric rating scale (NRS) PROs
were included in a Phase I trial of pexidartinib
(PLX3397), and the longitudinal trends in the results
are summarized descriptively.
Background Research
Targeted Literature Review
Two searches of the peer-reviewed literature were
conducted for publications describing relevant symp-
toms, PRO instruments, and/or information on the use
of PROs in clinical trials. The ﬁrst search was
conducted to identify publications that included either
clinical trials or case reports on TGCT. Because
TGCT is a rare disease, the literature describing
relevant PROs or supporting the psychometric proper-
ties of PROs in this patient population was expected
to be sparse. Therefore, a second search was con-
ducted in similar conditions including osteoarthritis,
rheumatoid arthritis, and meniscal tears. These ther-
apeutic areas were selected because the symptoms and
difﬁculties associated with these conditions (ie, stiff-
ness, swelling, pain, immobility) were expected to be
similar to those experienced by patients with TGCT.
Clinical Expert Interviews
Four clinicians with expertise in treating TGCT
participated in individual clinical expert interviews
(S.V.B., J.H.H, R.D.L., and W.D.T.). The experts
were asked for their input on: (1) the relevant
symptoms and impacts reported to them by their
patients with TGCT; (2) the proposed inclusion and
exclusion criteria for the qualitative study; and (3) the
potentially relevant PRO measures that had been780identiﬁed through the literature review or that they
additionally recommended for consideration.
Qualitative Interview Study
Participants
Due to the rare nature of the disease, a multimodal
recruitment strategy was pursued. Participants were
recruited either through a clinical site or identiﬁed
through online activity (eg, blogging, Internet posts on
disease-speciﬁc websites) as a potential person with
TGCT. Individuals recruited through the Internet were
asked to sign a release of medical information that
was sent to their treating physician for conﬁrmation of
their diagnosis.
Participants were eligible for the study if they were
able to participate in a 1-on-1 interview, were at least
18 years of age, had been diagnosed with PVNS or
GCT-TS (active present tumor or previously treated
tumor), were able to read and speak in English, and
were willing and able to provide informed consent.
Participants were ineligible if they had any signiﬁcant
impairment that could interfere with their ability to
provide consent or participate in the interview, or if
they had any systemic or local illness or medical
condition that could interfere with the participants’
perception of TGCT symptoms. This study was ap-
proved by a central institutional review board (Ethical &
Independent Review Services; Protocol 13061), and all
patients provided written informed consent.
Interview Procedures
The semi-structured interview guide for the qual-
itative study involving 1-on-1 in-person or telephone-
based interviews was developed on the basis of results
of the literature review and input from the clinical
experts. The interview guide included 2 main parts. The
ﬁrst part involved concept elicitation to identify the key
relevant symptom concepts and the effects of these
symptoms as experienced by patients. Open-ended
questions were included in the concept elicitation phase
of the interview and were intended to capture a broad
range of symptom and impact information from the
patient perspective.15 These initial questions asked
participants to talk about the location of their tumor,
the process of being diagnosed, treatments, the symptoms
they had experienced (description, frequency, variability,
and relationship with pain), and effects they had noticed.
The second part included a cognitive interview that was
designed to have the patients provide feedback onVolume 38 Number 4
H.L. Gelhorn et al.the content and their understanding of several
PRO instruments of potential relevance. This process
included questions for each instrument, speciﬁcally
probing participants about the relevance, instructions,
item content, recall period, and response options. All
interview discussions lasted 90 minutes and were
audio-recorded. At the conclusion of the interviews, the
participants were asked to complete a sociodemographic
and clinical form. Patients were remunerated for their
participation.
Measures
Although 46 PRO instruments were identiﬁed as
potentially relevant based on the background research
(eg, Lysholm knee scoring scale, Knee Injury and
Osteoarthritis Outcome Score, Short-Form 36), a
subset of these PROs were selected for further evalua-
tion in the qualitative study based on results of the
literature review and clinical expert input. The se-
lected instruments included the Western Ontario
and McMaster Universities Osteoarthritis Index
(WOMAC), symptom numeric rating scale (NRS)
items (ie, pain, stiffness, swelling, immobility, limited
motion), and the Patient Reported Outcomes Meas-
urement Information System (PROMIS) Physical
Function (PF) items. The instruments were selected
because they most closely and comprehensively cap-
tured the key symptoms and effects of TGCT as
reported in the literature and by the clinical experts.
Western Ontario McMaster Arthritis–Pigmented
Villonudular Synovitis and Giant Cell Tumor of the
Tendon Sheath Index
The Western Ontario McMaster Arthritis–Pig-
mented Villonodular Synovitis and Giant Cell Tumor
of the Tendon Sheath (WOMAC PVNS-GCTTS)
index, used in the current study, is a modiﬁed version
of the WOMAC Index NRS 3.1, a self-administered
24-item instrument assessing pain, stiffness, and difﬁ-
culty performing daily activities originally designed
for osteoarthritis.16,17 The WOMAC is focused on
assessing issues associated with lower extremity con-
ditions, mainly the knee and hip. All items are
measured on a 0- to 10-point NRS. The WOMAC
PVNS-GCTTS asks the same questions as the original
WOMAC but was adapted to speciﬁcally ask partic-
ipants to consider the symptoms at the “study joint/
tumor location.” This minor change to the WOMAC
was approved by the instrument developer.April 2016Symptom NRS Items
Patients were asked about pain, swelling, stiffness,
instability, and limited motion using a series of 0- to
10-point NRS items. Adapted from the Brief Pain
Inventory item that asks patients to rate their pain at
its worst in the last 24 hours,18 the NRS symptom
items asked the participants to “Please rate your
[insert symptom] by circling the one number that
best describes your [insert symptom] at its worst in the
past 24 hours.” The instructions indicated to
participants that the questions were about symptoms
at the site of their tumor. The anchors for the pain
scale were labeled 0 ¼ “no pain” and 10 ¼ “pain as
bad as you can imagine.” The scales for the other
symptoms were anchored with 0 ¼ “no swelling” (or
“no stiffness”) and 10 ¼ “worst imaginable.”
PROMIS-PF Assessment
The PROMIS-PF is an item bank comprising 121
self-administered items to assess physical functioning.
The items focus on the functioning of one’s upper
extremities (dexterity), lower extremities (walking
or mobility), central regions (neck and back), and
instrumental activities of daily living.19 All items
include a 5-point response scale. For capability ques-
tions, the response scale ranges from “without any
difﬁculty” to “unable to do.” For questions on
limitations, the response scale ranges from “not at
all” to “cannot do.” For the purposes of the present
study, participants did not complete the full instru-
ment; they were instead presented with a checklist of
121 PROMIS-PF items and were asked to indicate
which items were relevant to them based on their
experiences with TGCT. During the cognitive inter-
view portion of the semi-structured interview, the
patients were debriefed on 2 of the PROMIS-PF items
that were selected because it was anticipated that they
were likely to be relevant (ie, “Are you able to stand
for 1 hour?” and “Are you able to do chores such as
vacuuming or yard work?”)
Data Analysis
All interviews were audio-recorded and professio-
nally transcribed, and then reviewed for accuracy and
removal of any identifying information. A coding
dictionary was developed based on the themes and
concepts that emerged in the interviews. Coding of the
words and phrases into key themes, attributes, con-
cepts, and relationships was completed by using the781
Table I. Participant-reported sociodemographic
characteristics. Unless otherwise indicated,
values are given as no. (%).
Characteristic
Full Sample
(N ¼ 22)
Age, y
Mean (SD) 42.5 (9.0)
Median (minimum–maximum) 44.0 (27–56)
Male 6 (27)
Hispanic or Latino 2 (9)
Race*
White 21 (95)
Black or African American 0
Asian 0
Native Hawaiian or other
Paciﬁc Islander
0
American Indian or Alaskan
Native
0
Other 1 (5)
Marital status
Married 15 (68)
Single 7 (32)
Divorced/separated 0
Widowed 0
Clinical Therapeuticsconstant comparative method,20 an iterative coding
approach that involves moving through transcripts
consecutively and returning to previous transcripts as
new codes emerge. The qualitative analysis was
completed by using ATLAS.ti version 5.2 software.21
Outputs from the coded transcripts were used to
summarize the patient feedback in tabular format.
Descriptive statistics (mean, SD, and frequency) for
sociodemographic and clinical data were used to
characterize the sample.
Phase I Study
An ongoing open-label, single-arm, multicenter,
extension cohort of a Phase I trial of pexidartinib in
TGCT (Tap et al10 provides additional details) was
amended to include the symptom NRS items at ﬁrst
dose and ﬁrst day of each 4-week cycle; they were
also collected at 6 days before each of these visits.
Magnetic resonance imaging scans were evaluated
for local Response Evaluation Criteria in Solid
Tumors Version 1.1 assessment at screening and
every 8 weeks (every other treatment cycle). The
data cutoff date of the Phase I trial data that were
analyzed and presented in this manuscript was July
31, 2015.Other 0
Employment status
Employed, full-time or
part-time
13 (59)
Homemaker 3 (14)
Student 2 (9)
Unemployed 3 (14)
Retired 0
Disabled 1 (5)
Education
Elementary/primary school 0
Secondary/high school 0
Some college 4 (18)
College degree 15 (68)
Postgraduate degree 3 (14)
Technical or vocational degree 0
Other 0
* = options are not mutually exclusive.RESULTS
One-on-one in-person and telephone-based interviews
were conducted with 22 participants who had a mean
age of 42.5 years (range, 27–56 years); 73% (n ¼ 16)
were female. The locations of the participants’ tumors
included the knee (n ¼ 15 [68%]), hip (n ¼ 3 [14%]),
ankle (n ¼ 2 [9%]), elbow (n ¼ 1 [5%]), and forearm
(n ¼ 1 [5%]). Additional patient-reported sociodemo-
graphic and clinical characteristics are shown in
Tables I and II, respectively.
Concept Elicitation
Participants described a range of symptoms in the
concept elicitation portion of the interviews, many of
them spontaneously in response to the open-ended
questions at the beginning of the interview. Table III
displays a summary of the concept elicitation results,
both the spontaneously reported symptoms and those
elicited through probing. Pain and swelling were the
most commonly reported symptoms, each mentioned by
a majority (82% and 86%, respectively) of the
participants. Stiffness (73%), reduced range of motion782(64%), and joint instability or giving out/giving
way (64%) were also commonly mentioned by partici-
pants.Volume 38 Number 4
Table II. Participant-reported clinical characteristics. Values are given as no. (%).
Characteristic
Full Sample
(N ¼ 22)
Type of tumor
PVNS 19 (86)
GCT-TS 3 (14)
41 joint affected 0
Location of tumor
Knee (any region) 15 (68)
Knee (anterior) 4 (18)
Knee (anterior and posterior) 8 (36)
Knee (posterior) 2 (9)
Knee (anterior and posterior and side) 1 (5)
Hip 3 (14)
Ankle 2 (9)
Foot 0
Shoulder 0
Elbow 1 (5)
Hand 0
Wrist 0
Other* 1 (5)
Known procedures and medications to treat tumor†
Synovectomy 13 (59)
Arthroscopy 11 (50)
Other surgery type‡ 10 (45)
Drainage 6 (27)
Other§ 8 (36)
Narcotics 2 (9)
Anti-inﬂammatory drugs 8 (36)
Steroids 2 (9)
GCT-TS ¼ giant cell tumors of the tendon sheath; PVNS ¼ pigmented villonodular synovitis.
*Other area is forearm.
†Options are not mutually exclusive.
‡Other surgery types speciﬁed by study participants included: “ﬁrst time may have been synovectomy” (1); “six ankle
surgeries” (1); “anterior cruciate ligament replacement due to tumor damage” (1); “began as arthroscopy then opened me
up to remove the tumor” (1); “tumor removal” (1); “total knee replacement” (3); “hip replacement” (1).
§Other procedures speciﬁed included: biopsy; cortisone injection; radiation; external beam radiation therapy; injected radiation;
left total hip replacement 12-4-12; tumor removed surgically off of artiﬁcial joint site; and reported radiation beam.
H.L. Gelhorn et al.In general, participants used similar words to
characterize their experience of these symptoms and
reported day-to-day and within-day variability in
terms of presence/absence, frequency, and severity of
the symptoms. An example participant quote is below.April 2016“It was a general pain. Sometimes I wouldn’t feel it
at all, but I especially felt it if I was to squat down.
Then it just felt like, because of the tumors, that
there was too much soft tissue in my knee and it
wanted to expand out of the joint. It didn’t783
Table III. Patient-reported symptoms of tenosynovial giant cell tumor.
Tumor Present at Time of Interview Tumor Resected, Not Present at Time of Interview
Total
(N ¼ 22)
Participant ID No.: 008 001 007 015 016 017 018 019 024 022 025 002 004 005 006 010 011 012 014 020 021 023
Tumor Location:
L
knee
R
knee
L
elbow
L
ankle
R
knee
R
knee
R
knee
L
knee
L
knee
R
knee
L
knee
L
hip
L
hip
L
knee
L
knee
R
knee
L
knee
L
knee
L
ankle
R
knee
L
hip
R
forearm
Physician-conﬁrmed
diagnosis: Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Pain
Pain S S S - S S S S S S - S S S - S S S P S S - 18
Swelling - - - - - - - - - - - - - - - - - - - - - - -
Swelling S S P S S S S S S S P S - S S P S - P S - P 19
Limited motion - - - - - - - - - - - - - - - - - - - - - - -
Stiffness/tightness P - P P P S S - P S P S S S P - S P - - - P 16
Reduced ROM
problems with
extension/
ﬂexion
- - S S - S S S S S S - S S S - S - S - - P 14
Instability
Giving way/out - S P - S - S S - - - - S S - P P S P P S P 14
Instability P P P P - - P P - - P - P P - - S P S - - - 12
Terms related to
ease of movement
Catching S - P - - P - P - P - S P P P P P S - P P - 14
Locking S - S - - P - - - - - P - - - - S S - - - - 6
Sound during movement
Popping S S - S - P - S - - - S P S S P P S - - - - 12
Clicking S S S - - - - - - - - - - S - - - - - - - - 4
Grinding - - - - - - S - - - P S - - - - - - - - - - 3
Snapping - - - - - - - - - - - S - - - P - - - - - - 2
Cracking - - - S - - - - - - - - - - - S - - - - - - 2
Other symptoms/
terms†
- - - - - - - - - - - - - - - - - - - - - - -
(continued)
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Table III. (continued).
Tumor Present at Time of Interview Tumor Resected, Not Present at Time of Interview
Total
(N ¼ 22)
Participant ID No.: 008 001 007 015 016 017 018 019 024 022 025 002 004 005 006 010 011 012 014 020 021 023
Tumor Location:
L
knee
R
knee
L
elbow
L
ankle
R
knee
R
knee
R
knee
L
knee
L
knee
R
knee
L
knee
L
hip
L
hip
L
knee
L
knee
R
knee
L
knee
L
knee
L
ankle
R
knee
L
hip
R
forearm
Physician-conﬁrmed
diagnosis: Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Pressure - S S - - - - - S S - - - - S - - - - - - S 6
Weakened/
tired/ lack of
strength in
muscles
- - - - - - - - - S P - - S S - - - - - - S 5
Heat, hot to touch - - S - - - - S - - - - - S - - S - S - - - 5
Sensitivity/
Discomfort
- - - - - - S - - S - - - S - - - - S - - - 4
Enlargement
(solid)/cyst
- - - S - - - - S - S - - - - - - - - - - - 3
L ¼ left; R ¼ right; ROM ¼ range of motion.
*Symptoms that arise spontaneously are often the most relevant and severe; these are indicated by an “S.” Symptoms that participants indicated that they had
experienced only after probing from the interviewer are noted by a “P.” Symptoms not endorsed as part of the participant's experience either spontaneously or after
probing are indicated by a "-".
†Other symptoms reported by 1 participant each included: pulsating sensation, knot, cramps, rash/itchiness, irritated muscles, numbness, and fatigue/tiredness.
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Clinical Therapeuticsnecessarily look swollen to me, but it felt very full
and swollen.”
Cognitive Debriefing of PROs
WOMAC PVNS-GCTTS
Overall, participants with lower extremity tumors
found the WOMAC PVNS-GCTTS to be highly
relevant, easy to understand, and that the response
options and recall period of 48 hours were appropri-
ate. However, participants with upper extremity
tumors reported that the entire WOMAC PVNS-
GCTTS measure was not relevant to them. These
upper extremity tumor participants did indicate that
some of the other measures were relevant to them
(ie, NRS and PROMIS).
Some speciﬁc ﬁndings on individual WOMAC
PVNS-GCTTS items were noted. For example, the item
“getting in and out of a car, or getting on or off a bus”
was difﬁcult for some participants to answer because it
depended on the height of the vehicle. The 2 items
related to socks (“putting on socks” and “taking off
socks”) were less relevant to approximately one third
of the participants. In addition, there was considerable
variability and some confusion regarding the interpre-
tation of “heavy chores.” Finally, about one half of the
participants reported that they did not take baths (they
took showers); thus, this item was not relevant to them.
Symptom NRS Items
All participants understood the symptom NRS
items as intended and noted correctly that the ques-
tions were speciﬁc to the symptoms at the site of their
tumor. Participants were able to respond to the
questions with ease using the recall period and the
response scale provided. The 24-hour recall period
was conﬁrmed as appropriate because many partic-
ipants indicated that their experience of pain and
stiffness in particular varied within this time frame.
PROMIS-PF Items
A total of 54 items from the PROMIS-PF item bank
were identiﬁed as relevant by Z20% of the study
participants. Based on review of the PROMIS-PF item
checklists and the qualitative transcripts for speciﬁc
mention of effects on physical functioning, 15
PROMIS-PF items were identiﬁed that best captured
the impact of TGCT on physical functioning. In addition
to the relevance as endorsed by participants on the
PROMIS-PF checklist, selection of the items was also786strongly informed by the statements made by partici-
pants during both the concept elicitation and the
cognitive debrieﬁng portions of the qualitative inter-
views. These statements included whether the experience
was common, whether each item was sufﬁciently spe-
ciﬁc, and whether the impact/activity described was
likely to occur frequently (eg, on a daily basis).
Of the 15 identiﬁed items, the PROMIS-PF check-
list exercise revealed that 9 were endorsed as relevant
to participants with either upper or lower extremity
tumors (n ¼ 22) (carry a laundry basket up a ﬂight of
stairs [45% of the participants indicated that this item
was relevant on the PROMIS-PF checklist]; able to
exercise for 1 hour [55%]; able to dress oneself [5%];
health limits going outside of home [14%]; able to
push open a heavy door [36%]; able to carry a heavy
object 410 pounds [41%]; health limits doing mod-
erate work around the house [36%]; health limits
doing heavy work around the house [50%]; and
health limits lifting or carrying groceries [27%]).
According to the PROMIS-PF checklist exercise, 4
items were relevant only to participants with lower
extremity tumors (n ¼ 20) (able to walk at least 15
minutes [40%]; able to stand for 1 hour [60%]; able
to go up and down stairs at a normal pace [65%]; and
health limits bending, kneeling, and stooping [60%]).
Finally, there were 2 items endorsed as relevant during
the PROMIS-PF checklist exercise that were unique to
participants with upper extremity tumors (n ¼ 2) (able
to change a light bulb overhead [50%]; able to lift 10
pounds above one’s shoulder [50%]). Several of these
concepts, although endorsed by a smaller number of
participants during the PROMIS-PF checklist exercise,
were considered to be worthy of inclusion based on
the results of the qualitative interviews in which
additional participants noted that they were relevant.
These 15 physical functioning items from the
PROMIS-PF item bank were used to create physical
functioning measures speciﬁc to patients with either
upper extremity tumors (11 items) or lower extremity
tumors (13 items), including 9 items that overlapped
across both scales. Because the PROMIS-PF item
banks include information on the statistical properties
of the items (ie, the item slope and thresholds) that
have been estimated across the entire item bank by
using item response theory, the physical functioning
scores for each participant (regardless of tumor
location) can be scored on the same physical function-
ing metric and analyzed together.Volume 38 Number 4
H.L. Gelhorn et al.For the 2 PROMIS-PF items that were discussed
speciﬁcally during the interviews (stand for 1 hour,
and do chores such as vacuuming or yard work),
participants’ responses indicated that the items were
understood as intended, and that the response options
provided were acceptable.
Application of PRO Measures in a Phase I Trial
The pain and stiffness NRS measures were piloted
in an ongoing, single-arm, extension cohort of a Phase
I clinical trial of pexidartinib (NCT01004861). The
patient population and primary results of the clinical
trial have been previously reported.10 Twenty-three
patients with advanced TGCT were enrolled into the
extension cohort and completed PROs at baseline and
on-treatment. The mean age was 44 years, and 13
(56%) were female. The location of tumors was as
follows: 12 (52%) knee, 5 (22%) hip/thigh, 3 (13%)
ankle, and 1 (4%) each of elbow, forearm, and wrist;
1 patient with a knee lesion also had metastatic
disease. Seventeen patients had undergone surgery
previously; 1 patient had had prior radiation therapy.
Descriptive results of the mean change in the pain
and stiffness NRS items from baseline through week
25 are shown in Figures 1 and 2, respectively. These
graphics display a consistent trend of decreased scores
(ie, improvement) in both pain and stiffness over time
from baseline through week 25.
Additional analyses of the Phase I data were
conducted by using a responder deﬁnition of 30%
change in each NRS score from baseline to week 25;−5
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April 2016the proportion of responders for the pain and stiffness
end points were calculated. Of the 15 participants
with both baseline and week 25 NRS data, 10 (66%)
were responders for the pain end point, and 11 (73%)
were responders for stiffness. Of all participants with
baseline NRS data (including dropouts and incom-
pletes at week 25; n = 23), 43% were responders for
pain, and 48% were responders for stiffness.
Scatterplots of change in NRS scores according to
change in tumor size for patients with baseline and week
25 data are shown in Figures 3 and 4. These ﬁgures
suggest a strong relationship between the radiologic
outcome (tumor size change) and the patient-reported
pain and stiffness outcomes in the Phase I data.DISCUSSION
To our knowledge, this study is the ﬁrst to gather
information directly from patients with TGCT regard-
ing the disease-speciﬁc symptoms and effects associ-
ated with the condition. The study was motivated by
the need to support and complement the meaningful-
ness to patients of changes in a clinical/radiologic end
point (ie, tumor volume) in response to a novel
treatment. In a disease such as TGCT, which is rarely
lethal and where the affected population is generally
younger than in many other malignancies that result
in death, systemic treatment could be given for years;
thus, understanding the impact of therapies and the
relevance of treatment outcomes to patients’ quality of
life is essential.11eek 13 
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H.L. Gelhorn et al.The results from this study suggest that pain,
swelling, and stiffness are the most common and
important symptoms from the perspective of pa-
tients with TGCT. Reduced range of motion, in-
stability, giving out, and catching were also
commonly mentioned. Patients reported a wide
range of effects on their physical functioning as a
consequence of these symptoms. These ﬁndings are
consistent with clinical expert input regarding
important TGCT symptoms and effects. It is inter-
esting to note that, because TGCT is a rare con-
dition, even the clinical experts were unable to
provide a sufﬁciently comprehensive and speciﬁc
characterization of the disease and its effects to
conﬁdently select PRO measures without gathering
input directly from patients.
Although there were symptoms that emerged as
clear hallmarks of the disease, there was evidence ofApril 2016variability in the symptom experience. Not all patients
experience all symptoms (eg, swelling but not pain, or
pain and swelling but not stiffness or reduced range of
motion). There is also variability in how patients
experience the symptoms within and among days.
The evidence of variability based on the descriptions
provided by patients reﬂects the need for brief recall
periods in assessing these symptoms. Not all of the
symptoms may be best assessed through patient self-
report; for example, swelling may be best measured
morphometrically in the clinic. Clinical measurement
of swelling is likely to be more objective; in addition,
several of the patients reported that swelling as a
symptom was relevant to them primarily because of
the consequent pain, stiffness, or impairment in
physical functioning. The sample for this study in-
cluded participants with active disease and others who
had previously resected tumors; however, no differences789
Clinical Therapeuticswere noted in the concept elicitation or cognitive
debrieﬁng results based on tumor status (Table III).
Patients reported a range of limitations to their
physical functioning as a consequence of their TGCT
that varied depending on the location of the tumor.
This scenario presented a challenge in identifying an
instrument that would cover the range of effects
associated with multiple, different tumor locations
(ie, upper extremity vs lower extremity). Selection of
a subset of the items from the PROMIS-PF item bank,
with 1 item set for the upper extremity population and
a second item set for the lower extremity population,
was informed both by direct patient input and with
consideration for the statistical properties of the
individual candidate items. The item-speciﬁc charac-
teristics were available on the PROMIS website and
were estimated by the developers by using item
response theory. This approach provides the ﬂexibility
needed to assess a common concept (ie, impact on
physical functioning), using a common metric (ie, a
latent physical functioning trait), in a heterogeneous
sample of patients. These 2 PROMIS-PF item subsets
have been included as outcome measures in the
ongoing Phase III clinical trial of patients with TGCT
(NCT02371369).
We used literature reviews, clinical expert input,
direct interviews with patients, and existing banks of
items with known measurement properties to select
subsets of items appropriate for the measurement of a
single concept (physical functioning) in a heteroge-
neous population of patients. This measurement ap-
proach may be particularly appealing to researchers in
oncology who encounter similar rare and/or hetero-
geneous populations in their research; for example, in
studies of rare conditions in which subgroup analyses
are either infeasible or impractical.
This approach is only feasible when there are
existing item banks for the concept of interest that
include high-quality and well-characterized items.
PROMIS investigators followed standardized and
rigorous methods to develop the repository of physical
functioning items that can be administered as a
tailored tool for the population of interest. Develop-
ment of the PROMIS-PF item bank involved the initial
identiﬁcation of 1860 items.22 The best-ﬁtting
PROMIS-PF items were selected by using item re-
sponse theory and conﬁrmatory factor analysis, yield-
ing an item bank of the most relevant, clearest, and
best understood items. The use of the PROMIS-PF790item bank in the manner described is consistent with
one of the stated objectives of the National Institutes
of Health PROMIS Initiative, which is to establish a
national resource for accurate and efﬁcient PRO
measurement.23
In testing, developing, and using PRO instruments
in a novel treatment development process, it is
important to follow guidance on PRO measures issued
by the US Food and Drug Administration (FDA) and
the European Medicines Agency24,25 and to engage
with regulatory agencies early. The recommendations
in the FDA’s PRO guidance, which are labeled by the
FDA as nonbinding, may be viewed as challenging
and unrealistic for those studying rare diseases. The
approaches taken in the present study offer some
viable alternatives to the more direct and comprehen-
sive approaches that are only feasible with more
common diseases. Some examples of these alternatives
are: (1) review of the literature and existing PRO
measures (eg, PROMIS-PF item bank) from other
disease areas in which there are relevant parallels
between patients’ experiences of symptoms and effects
(ie, literature for osteoarthritis, rheumatoid arthritis,
and meniscal tears); (2) soliciting additional input
from clinical experts to guide the research and support
content validity when the ability to gather input
directly from patients is limited; and (3) a greater
degree of ﬂexibility in recruitment and interviewing
methods and in determination of acceptable sample
sizes given the difﬁculties of conducting research in
rare diseases. The exact methodology for gathering
and summarizing evidence to support the use of PROs
is not detailed but is broadly discussed in the FDA
guidance. In addition, the experience of our team with
this particular study of TGCT suggests that there is
ﬂexibility and understanding on the part of regulators
in the determination of acceptable approaches and
methodologies for gathering reasonable evidence. For
this particular program of research, interactions with
regulatory agencies were helpful in selecting appro-
priate end point concepts and measures, positioning of
the PROs in the end point hierarchy, and reaching
agreement on the appropriate methods for the analysis
of the data. There is also value in communicating with
regulatory agencies early on and regularly throughout
the development process; thus, any issues can be
discussed and addressed, in particular where consid-
eration for the challenges associated with conducting
research in rare diseases is warranted.Volume 38 Number 4
H.L. Gelhorn et al.Various limitations of this study merit mention.
Our recruitment strategy included the identiﬁcation of
patients through online blogging and website posts.
This approach introduces a potential selection bias in
that individuals who blog and post online may be
systematically different in terms of their symptom
experiences from those who do not interact online.
Our online recruitment efforts resulted in the identi-
ﬁcation of only female subjects; recruitment from
clinical sites was necessary to identify male partici-
pants with TGCT. There were no apparent differences
between the sexes in their reports of the symptoms or
effects of TGCT. Recruitment of patients with a rare
disease can be extremely challenging. The recruitment
methods used in this study, although not without
inherent limitations, were used to successfully recruit
an adequate sample of patients with consideration for
practical issues relevant to all research, namely time
and ﬁnancial constraints. This recruitment strategy
may be an acceptable primary or supplementary
strategy in future studies of similarly rare disease
populations. Although some participants were inter-
viewed in-person while others were interviewed over
the telephone, we found no speciﬁc differences in the
nature or quality of the information gathered. This
outcome suggests that telephone interviews may be an
acceptable approach for interviewing patients with
rare conditions when access to patients across a large
geographical area presents a signiﬁcant challenge. An
additional limitation is that 5 participants did not
have a clinician-conﬁrmed diagnosis of TGCT; how-
ever, comparison of the results across the 2 groups did
not suggest any noticeable differences. Finally, we
were unable to recruit a sample of patients represent-
ing all bodily locations that can be affected by TGCT.
For example, no patients experienced a tumor in the
jaw or spine, and only 2 tumors were located in the
upper extremities. As a consequence, there were some
assumptions made about the nature and extent of the
effects of TGCT on physical functioning for patients
with upper extremity tumors; this may be an area for
further research. It is important to note, however, that
the distribution of upper versus lower extremity
tumors in our sample (ie, 90% lower extremity) is
consistent with the prevalence in the target popula-
tion, in which a high percentage of the tumors affect
large joints, especially the knee.2
We encourage replication of the methods reported
in this study toward the goal of meeting the need toApril 2016identify relevant PRO measures for other oncology
indications. The approach taken for this study al-
lowed for the identiﬁcation of existing PRO measures
from other therapeutic areas and the adaptation and
application of those measures, as appropriate, for
TGCT. Use of the NRS items that were adapted for
the Phase I clinical trial of pexidartinib is supported by
the data presented herein, which suggest a strong
relationship between the clinical/radiologic outcome
(tumor size change) and the NRS patient-reported
pain and stiffness outcomes. Areas for future research
in TGCT include an exploration of the relationships
between PROs and other clinical factors such as bulk
of disease, past procedures, tumor location, duration
of disease, tumor size, and analgesic medication use.
Data from the ongoing Phase III trial of pexidartinib
(NCT02371369) among patients with TGCT may
provide an opportunity to investigate these relation-
ships and may provide additional insights into the
value and appropriate use of PRO measures in this
rare disease patient population. In addition, further
evaluation of the content validity of the selected
PROMIS-PF items is ongoing.CONCLUSIONS
This study is the ﬁrst, to the best of our knowledge, to
gather information directly from patients with TGCT
regarding their symptom experiences. The ﬁndings of
this study show that several PRO instruments may be
useful in assessing the effects of treatments for TGCT
from the patient perspective. Based on the results, the
pain and stiffness NRS items and speciﬁcally tailored
PROMIS-PF PROs have been identiﬁed as the most
appropriate measures. In a Phase I trial, the pain and
stiffness PRO measures were included on an explor-
atory basis, and early results suggest that they effec-
tively measure improvements from the patient
perspective. These instruments are being incorporated
into a Phase III clinical trial as important secondary
end points to support the meaningfulness of reduction
in tumor volume.ACKNOWLEDGMENTS
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